HOME >> BIOLOGY >> NEWS
CSHL links activity in brain synapses and developmental abnormalities with schizophrenia gene

Cold Spring Harbor, NY Cold Spring Harbor Laboratory (CSHL) researchers have identified a function of neuregulin1 (NRG1), a gene previously linked to schizophrenia but whose role in the disease was unknown. "We found that when this gene or this pathway is impaired," explained CSHL's Bo Li. "It starts a chain reaction negatively impacting synapses in the brain which contribute to the abnormal development of brain circuits and may lead to schizophrenia."

By discovering the connections between genes and how they impact synapses and circuits in the brain, research is guiding the development of new strategies to diagnose and treat neurological disease. Published on May 24, 2007 in the journal Neuron, this latest research supports the hypothesis that schizophrenia is a disease that results from multiple factors, including genetic defects and developmental abnormalities in the brain. A lynchpin in the development of the disease is the brain's neurotransmitter system known as the glutamate system. When the glutamate system is suppressed it leads to abnormal brain development and schizophrenic symptoms.

Unlocking the mystery of NRG1 and its critical function in the normal development of the glutamate system was the result of a unique combination of technologies at CSHL. Under the direction of CSHL's Neuroscience Research Program Chair, Robert Malinow, M.D., Ph.D., researchers inform their study of diseased brains by the ongoing study of normal brains. "The ability to finally identify the functionality of NRG1 was possible here because of access to powerful technology that combined the ability to manipulate individual genes, to study the very structure of the glutamate synapse with a two-photon microscope, and to perform functional studies using electrophysiology."

Li hopes that his research will stimulate more exploration of the functions of NRG1 in the brain. "This gene and its pathway also have implications for other neurol
'"/>

Contact: Dagnia Zeidlickis
zeidlick@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
24-May-2007


Page: 1 2

Related biology news :

1. New textbook illuminates the close links between evolutionary and molecular biology
2. Preclinical study links gene to brain aneurysm formation
3. UCF research links proteins, stem cells and potential Alzheimers treatment
4. New mechanism links smoking to lung damage
5. UCLA study links air pollution to clogged arteries
6. University of Leeds strengthens China links in membrane and neurobiology
7. Satellite survey links tropical park fires with poverty and corruption
8. Genetic defect links respiratory disease and congenital heart disease
9. West African Ocean sediment core links monsoons to global climate evolution
10. Salk researchers discover first gene that specifically links calorie restriction to longevity
11. A new study links a stomach microbe to asthma prevention

Post Your Comments:
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: